These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 27838289)

  • 1. Biopharmaceuticals from microorganisms: from production to purification.
    Jozala AF; Geraldes DC; Tundisi LL; Feitosa VA; Breyer CA; Cardoso SL; Mazzola PG; Oliveira-Nascimento L; Rangel-Yagui CO; Magalhães PO; Oliveira MA; Pessoa A
    Braz J Microbiol; 2016 Dec; 47 Suppl 1(Suppl 1):51-63. PubMed ID: 27838289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biosimilars: opportunity or cause for concern?
    Roger SD; Mikhail A
    J Pharm Pharm Sci; 2007; 10(3):405-10. PubMed ID: 17727803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biopharmaceutical benchmarks 2018.
    Walsh G
    Nat Biotechnol; 2018 Dec; 36(12):1136-1145. PubMed ID: 30520869
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmaceutical biotechnology products approved within the European Union.
    Walsh G
    Eur J Pharm Biopharm; 2003 Jan; 55(1):3-10. PubMed ID: 12551698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biopharmaceuticals derived from genetically modified plants.
    Goldstein DA; Thomas JA
    QJM; 2004 Nov; 97(11):705-16. PubMed ID: 15496527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilars: recent developments.
    Covic A; Kuhlmann MK
    Int Urol Nephrol; 2007; 39(1):261-6. PubMed ID: 17333516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biopharmaceuticals in China.
    Hu X; Ma Q; Zhang S
    Biotechnol J; 2006 Nov; 1(11):1215-24. PubMed ID: 17089435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The biopharmaceutical industry in China: history and future perspectives.
    Gao K; Wang J
    Front Med; 2012 Jun; 6(2):101-11. PubMed ID: 22544299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Brief Talk on the Design of Biopharmaceutical Separation and Purification Technology Course.
    He Y; White M; Gang W; Yan S
    J Healthc Eng; 2022; 2022():9728071. PubMed ID: 35087652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the potential of machine learning for more efficient development and production of biopharmaceuticals.
    Puranik A; Dandekar P; Jain R
    Biotechnol Prog; 2022 Nov; 38(6):e3291. PubMed ID: 35918873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developments and opportunities in continuous biopharmaceutical manufacturing.
    Khanal O; Lenhoff AM
    MAbs; 2021; 13(1):1903664. PubMed ID: 33843449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioreactor technology: a novel industrial tool for high-tech production of bioactive molecules and biopharmaceuticals from plant roots.
    Sivakumar G
    Biotechnol J; 2006 Dec; 1(12):1419-27. PubMed ID: 17136730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous downstream processing of biopharmaceuticals.
    Jungbauer A
    Trends Biotechnol; 2013 Aug; 31(8):479-92. PubMed ID: 23849674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-Based Biopharmaceuticals: Overview on the Production, Purification, and Formulation.
    Castro LS; Lobo GS; Pereira P; Freire MG; Neves MC; Pedro AQ
    Vaccines (Basel); 2021 Apr; 9(4):. PubMed ID: 33915863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the Immunogenicity of Biopharmaceuticals.
    Pineda C; Castañeda Hernández G; Jacobs IA; Alvarez DF; Carini C
    BioDrugs; 2016 Jun; 30(3):195-206. PubMed ID: 27097915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Production of Biopharmaceuticals in E. coli: Current Scenario and Future Perspectives.
    Baeshen MN; Al-Hejin AM; Bora RS; Ahmed MM; Ramadan HA; Saini KS; Baeshen NA; Redwan EM
    J Microbiol Biotechnol; 2015 Jul; 25(7):953-62. PubMed ID: 25737124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Market of Biopharmaceutical Medicines: A Snapshot of a Diverse Industrial Landscape.
    Moorkens E; Meuwissen N; Huys I; Declerck P; Vulto AG; Simoens S
    Front Pharmacol; 2017; 8():314. PubMed ID: 28642701
    [No Abstract]   [Full Text] [Related]  

  • 18. Biotechnological Production of Pharmaceuticals and Biopharmaceuticals in Plant Cell and Organ Cultures.
    Hidalgo D; Sanchez R; Lalaleo L; Bonfill M; Corchete P; Palazon J
    Curr Med Chem; 2018; 25(30):3577-3596. PubMed ID: 29521202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plants as bioreactors for biopharmaceuticals: regulatory considerations.
    Miele L
    Trends Biotechnol; 1997 Feb; 15(2):45-50. PubMed ID: 9081298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant plant-derived pharmaceutical proteins: current technical and economic bottlenecks.
    Sabalza M; Christou P; Capell T
    Biotechnol Lett; 2014 Dec; 36(12):2367-79. PubMed ID: 25048244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.